This phase 1 clinical trial looked at the safety, tolerability, and the effectiveness of a new medicine called telaglenastat (a glutaminase inhibitor) in combination with everolimus or cabozantinib in patients with metastatic renal cell carcinoma (RCC) who had already been treated for their cancer.

There were 26 patients in the telaglenastat plus everolimus group and 13 in the telaglenastat plus cabozantinib group. For both groups, most side effects were mild or moderate needing no treatment or minimal treatment. The maximum tolerated dose of telaglenastat (800 mg twice a day) was not reached for either combination.

In the people in the teleglenastat plus everolimus group, their disease was controlled (complete or partial response or stable disease) in 95.2 % of patients with clear cell RCC and 66.7% in those with papillary RCC. In the teleglenastat plus cabozantinib group, disease control rate was 100% for both clear cell and papillary RCC.

This study shows promising safety, tolerability and effectiveness of telaglenastat with cabozantinib or everolimus in patients with advanced or metastatic RCC who had already been treated for their cancer.

Read more in Practice Update here